Damora Therapeutics, Inc. earned $3.98 per diluted share in fiscal year 2025. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $9.45 per diluted share. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Damora Therapeutics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)$3.98
Ticker history: GLTO became
DMRA
(Damora Therapeutics, Inc.) on .
Earlier news and filings retain their original names and dates.
View GLTO history.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Damora Therapeutics, Inc. earned $3.98 per diluted share in fiscal year 2025.
Damora Therapeutics, Inc. (DMRA) reported $9.45 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 7 fiscal years this page covers, Damora Therapeutics, Inc. (DMRA) diluted earnings per share went from -$161.82 in fiscal year 2019 to $3.98 in fiscal year 2025.
Damora Therapeutics, Inc. (DMRA) reported -$0.40 in diluted earnings per share in Q3 2026.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Damora Therapeutics, Inc. (DMRA) reported on that line in every period on record.
